Portal de Periódicos da CAPES

Open Targets Platform: supporting systematic drug–target identification and prioritisation

2020; Oxford University Press; Volume: 49; Issue: D1 Linguagem: Inglês

10.1093/nar/gkaa1027

1362-4962

David Ochoa, Andrew Hercules, Miguel Carmona, Dániel Süveges, Asier Gonzalez‐Uriarte, Claudio Malangone, Alfredo Miranda, Luca Fumis, Denise Carvalho‐Silva, Michaela Spitzer, Jarrod Baker, Javier Ferrer, Arwa Bin Raies, Olesya Razuvayevskaya, Adam Faulconbridge, Eirini Petsalaki, Prudence Mutowo, Sandra Machlitt‐Northen, Gareth Peat, Elaine McAuley, Chuang Kee Ong, Edward Mountjoy, Maya Ghoussaini, Andrea Pierleoni, Eliseo Papa, Miguel Pignatelli, Gautier Koscielny, Mohd Anisul Karim, Jeremy Schwartzentruber, David G. Hulcoop, Ian Dunham, Ellen M. McDonagh,

Biosimilars and Bioanalytical Methods

The Open Targets Platform (https://www.targetvalidation.org/) provides users with a queryable knowledgebase and user interface to aid systematic target identification and prioritisation for drug discovery based upon underlying evidence. It is publicly available and the underlying code is open source. Since our last update two years ago, we have had 10 releases to maintain and continuously improve evidence for target-disease relationships from 20 different data sources. In addition, we have integrated new evidence from key datasets, including prioritised targets identified from genome-wide CRISPR knockout screens in 300 cancer models (Project Score), and GWAS/UK BioBank statistical genetic analysis evidence from the Open Targets Genetics Portal. We have evolved our evidence scoring framework to improve target identification. To aid the prioritisation of targets and inform on the potential impact of modulating a given target, we have added evaluation of post-marketing adverse drug reactions and new curated information on target tractability and safety. We have also developed the user interface and backend technologies to improve performance and usability. In this article, we describe the latest enhancements to the Platform, to address the fundamental challenge that developing effective and safe drugs is difficult and expensive.